HomeLAN: An international online survey to assess satisfaction with injection experience of patients with neuroendocrine tumors (NETs) enrolled in lanreotide autogel (LAN) Patient Support Programmes (PSPs)

#3500

Introduction: LAN is a long-term treatment for NETs, delivered in a ready-to-use syringe by monthly, deep subcutaneous injection. LAN PSPs aim to assist patients receiving their treatment at home, reducing both travel burden and the current risk of COVID-19 exposure. Furthermore, after training patients on stable dose can administer LAN independently (self or non-healthcare professional), where approved.

Aim(s): Describe satisfaction with injection experience of patients enrolled in LAN PSPs and the impact of administration in the home setting.

Materials and methods: A non-interventional, cross-sectional survey of adults with NETs, enrolled in PSPs for ≥6 months and receiving LAN at home. Target sample size was 120, based on the number of patients in the PSPs and a 15% response rate. Endpoints included patient satisfaction with the most recent LAN injection (primary) and reasons for choosing their mode of administration.

Conference:

Presenting Author: Hernando J

Authors: Hernando J, Kolarova T, Verslype C, Kaltsas G, Houchard A,

Keywords: neuroendocrine tumor, patient satisfaction, patient support programme, patient survey, lanreotide autogel,